|
Getting your Trinity Audio player ready...
|
Halberd Corporation (OTC: HALB) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”. The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease and Cancer treatments.
Market Stats
On Tuesday, HALB stock fell 1.94% to $0.0101 with more than 870K shares, compared to its average volume of 1.57 million shares. The stock moved within a range of $0.0097 – 0.0110 after opening trading at $0.0108.
Over the course of the year so far, Halberd Corporation has made a lot of progress in terms of its research activities and has been in the news for the right reasons. That being said, the company has also been active on the operational front and yesterday it made another announcement regarding a new strategic alliance. The company announced yesterday that the strategic alliance in question is with Stem of Hope and AI Longevity Inc. By way of this alliance, the company is going to collaborate in a new fully owned subsidiary unit named Extendalife. The aim of the venture is going to be the development of treatments that would help in boosting longevity.
In addition to that, the venture is also going to be involved with the development of treatments for cancer and Alzheimer’s disease. The development of these treatments are going to be made through collaboration and will involve the patented as well as patent-pending technologies of the members of the alliance. The subsidiary is going to have personnel from all three companies. While the extracorporeal technology from Halberd is going to be combined with the work-to-date technology of AI Longevity and the stem cell research from Stem of Hope.
In addition to that, it was also noted by the AI Longevity Chief Executive Officer Gabe Vlad that he was looking to develop a Longevity Index App. The Chief Technology Officer of Halberd, Mitchell Felder, spoke about the company’s plans as well. Felder noted that before the year comes to an end, the company is going to start working on animal testing. The latest venture could well prove to be an important one for Halberd in the long run. It could well be a good idea for investors to consider adding the stock to their watch lists.
Traders Corner
HALB stock is trading below the 50-Day and 200-Day Moving averages of $0.0108 and $0.0117 respectively. Moreover, the stock is trading below the 20-Day moving average of $0.0171.
Related posts:
Human Unitec International, Inc. (OTCMKTS:HMNU) Announces Medical Equipment Deal in China Closed Up 17.78% 10x Volume: RSHN, ALST, HALB, EPAZ
Halberd Corporation (OTCMKTS:HALB) Stock Moves Back Above 50-Day MA on Big News
Pennies @ 52-Week Lows Time to Buy: ZRFY, HALB, MMMW, ALST, HMNU, CEOS
2023 Medical Stocks to Watch Under 1¢ Now! HALB, GRST, HMNU
Halberd (OTC:HALB) Eradicates 99.5% of CDC Provided Antibiotic Resistant Bacteria